A Study Comparing the Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution With PREPOPIK® for Colon Cleansing in Preparation for Colonoscopy
This study is currently recruiting participants.
Verified June 2017 by Ferring Pharmaceuticals
Sponsor:
Ferring Pharmaceuticals
Information provided by (Responsible Party):
Ferring Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT03017235
First received: January 9, 2017
Last updated: June 19, 2017
Last verified: June 2017
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to compare the Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution with PREPOPIK® for colon cleansing in adult subjects undergoing colonoscopy.
| Condition | Intervention | Phase |
|---|---|---|
| Bowel Preparation | Drug: Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution Drug: Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Powder | Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Outcomes Assessor Primary Purpose: Other |
| Official Title: | A Randomized, Assessor-Blinded, Multi-Center Study Investigating the Efficacy, Safety, and Tolerability of Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution Versus Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Powder for Oral Solution (PREPOPIK®) for Colon Cleansing in Preparation for Colonoscopy |
Resource links provided by NLM:
MedlinePlus related topics:
Colonoscopy
Drug Information available for:
Citric acid, anhydrous
Sodium citrate
Magnesium oxide
Citric acid monohydrate
Magnesium
Sodium Picosulfate
U.S. FDA Resources
Further study details as provided by Ferring Pharmaceuticals:
Primary Outcome Measures:
- Proportion of subjects classified as a responder defined by "excellent" or "good" [ Time Frame: At day of colonoscopy ]Measured by the Modified Aronchick scale
Secondary Outcome Measures:
- Proportion of subjects classified as a responder defined by a score ≥2 in the right segment of the colon [ Time Frame: At day of colonoscopy ]Measured by the Boston Bowel Preparation Scale (BBPS)
- Proportion of subjects classified as a responder defined by a score ≥2 in the transverse segment of the colon [ Time Frame: At day of colonoscopy ]Measured by the BBPS
- Proportion of subjects classified as a responder defined by a score ≥2 in the left segment of the colon [ Time Frame: At day of colonoscopy ]Measured by the BBPS
- Frequency of each category on the Subject Tolerability Questionnaire [ Time Frame: At day of colonoscopy ]Measured by the Mayo Clinic Bowel Prep Tolerability Questionnaire
- Incidence of treatment-emergent adverse events(AEs) [ Time Frame: From baseline (screening) up to day 28 after colonoscopy ]Collected as any AE that begins during the treatment period defined as the period during which a subject receives IMP
- Clinically significant changes in vital signs [ Time Frame: From baseline (screening) up to day 28 after colonoscopy ]Blood pressure and pulse will be measured after at least 5 minutes of rest in supine position and after 3 minutes in standing position
- Clinically significant changes in electrocardiogram (ECG) [ Time Frame: From baseline (screening) up to day 28 after colonoscopy ]Measured by standard 12-lead ECG
- Clinically significant changes in laboratory values [ Time Frame: From baseline (screening) up to day 28 after colonoscopy ]Rated by the investigator based on out of range laboratory values
| Estimated Enrollment: | 900 |
| Actual Study Start Date: | February 20, 2017 |
| Estimated Study Completion Date: | October 2017 |
| Estimated Primary Completion Date: | September 2017 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: NaP/MC Oral Solution
Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid (NaP/MC) Oral Solution
|
Drug: Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution
Supplied as ready-to-drink without further reconstitution before administration
|
| Active Comparator: PREPOPIK® |
Drug: Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Powder
Supplied as two packets per subject. Subjects will be instructed to reconstitute the medication by combining the contents of one packet with approximately five (5) ounces of cold water and stirring for two to three minutes.
Other Names:
|
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Male or non-pregnant female subjects aged 18 to 80 years, inclusive, being scheduled to undergo elective colonoscopy
- Females of childbearing potential must agree to use an adequate contraception during the course of the trial. Accepted forms of contraception are: i.e., implants, injectables, hormonal intrauterine device, combined hormonal contraceptives, sexual abstinence, and vasectomized sexual partner. Premenopausal women who are of childbearing potential must have a negative serum pregnancy test result at screening and a negative urine pregnancy test result at randomization prior to colonoscopy. In the case of oral contraceptive use, women should have been taking the same pill consistently for a minimum of twelve (12) weeks before taking study medication. Sterilized or postmenopausal women may also participate. Women are considered to be postmenopausal and are not considered to be of childbearing potential if they have had twelve (12) months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation.
- An average of at least 3 spontaneous bowel movements per week for one month prior to the colonoscopy
Exclusion Criteria:
- Known or suspected gastrointestinal obstruction, perforation, ileus, or gastric retention
- Acute intestinal or gastric ulceration
- Severe acute inflammatory bowel disease (IBD), toxic colitis, or toxic megacolon
- Undergoing colonoscopy for foreign body removal or decompression
- Reduced level of consciousness or inability to swallow without aspiration
- Any prior colorectal surgery, excluding appendectomy, hemorrhoid surgery, or prior endoscopic procedures
- Upper gastrointestinal surgery (gastrectomy, gastric banding, gastric by-pass)
- Uncontrolled angina and/or myocardial infarction (MI) within last three months, congestive heart failure (CHF), uncontrolled hypertension, or ascites
- Severely reduced renal function (<30 mL/min/1.73 m2)
- Pregnant or lactating women
- Any clinically relevant abnormal findings in medical history, physical examination, vital signs, ECG, clinical chemistry, hematology, coagulation, or urinalysis at Screening Visit 1
- Rhabdomyolysis
- Chronic nausea and vomiting
- Hypermagnesemia
- Undergoing treatment with Lithium
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT03017235
Please refer to this study by its ClinicalTrials.gov identifier: NCT03017235
Contacts
| Contact: Clinical Development Support | +1 833-548-1402 (US/Canada) | DK0-Disclosure@ferring.com | |
| Contact: Clinical Development Support | +1 862-286-5200 (outside US) | DK0-Disclosure@ferring.com |
Locations
| United States, Alabama | |
| Clinical Research Associates | Recruiting |
| Huntsville, Alabama, United States, 35801 | |
| United States, California | |
| Associated Gastroenterology Medical Group | Recruiting |
| Anaheim, California, United States, 92801 | |
| GW Research, Inc. | Recruiting |
| Chula Vista, California, United States, 91910 | |
| Precision Research Institute | Recruiting |
| San Diego, California, United States, 92114 | |
| United States, Connecticut | |
| Connecticut Clinical Research Foundation | Recruiting |
| Bristol, Connecticut, United States, 06010 | |
| United States, Florida | |
| Florida Clinical Research Group | Recruiting |
| Clearwater, Florida, United States, 33759 | |
| Nature Coast Clinical Research | Recruiting |
| Inverness, Florida, United States, 34452 | |
| United States, New York | |
| Long Island Gastrointestinal Research Group LLC | Recruiting |
| Great Neck, New York, United States, 11023 | |
| United States, North Carolina | |
| Kinston Medical Specialists, PA | Recruiting |
| Kinston, North Carolina, United States, 28501 | |
| Wake Research Associates, LLC | Recruiting |
| Raleigh, North Carolina, United States, 27612 | |
| United States, Pennsylvania | |
| Hillmont GI | Recruiting |
| Flourtown, Pennsylvania, United States, 19031 | |
| United States, Utah | |
| Advanced Research Institute | Recruiting |
| Ogden, Utah, United States, 84405 | |
| Canada | |
| Hotel Dieu Hospital | Recruiting |
| Kingston, Canada, K7L 5G2 | |
| Canadian Phase Onward, Inc. | Recruiting |
| Toronto, Canada, M3J 2C5 | |
Sponsors and Collaborators
Ferring Pharmaceuticals
Investigators
| Study Director: | Clinical Development Support | Ferring Pharmaceuticals |
More Information
| Responsible Party: | Ferring Pharmaceuticals |
| ClinicalTrials.gov Identifier: | NCT03017235 History of Changes |
| Other Study ID Numbers: |
000253 |
| Study First Received: | January 9, 2017 |
| Last Updated: | June 19, 2017 |
| Studies a U.S. FDA-regulated Drug Product: | Yes | |
| Studies a U.S. FDA-regulated Device Product: | No | |
Additional relevant MeSH terms:
|
Pharmaceutical Solutions Citric Acid Picosulfate sodium Magnesium Oxide Anticoagulants Calcium Chelating Agents |
Chelating Agents Sequestering Agents Molecular Mechanisms of Pharmacological Action Cathartics Gastrointestinal Agents Antacids |
ClinicalTrials.gov processed this record on July 17, 2017


IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
